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Background: Acute respiratory distress syndrome (ARDS) is associated with high in-hospital mortality. Alveolar
recruitment followed by ventilation at optimal titrated PEEP may reduce ventilator-induced lung injury and improve
oxygenation in patients with ARDS, but the effects on mortality and other clinical outcomes remain unknown. This
article reports the rationale, study design, and analysis plan of the Alveolar Recruitment for ARDS Trial (ART).
Methods/Design: ART is a pragmatic, multicenter, randomized (concealed), controlled trial, which aims to
determine if maximum stepwise alveolar recruitment associated with PEEP titration is able to increase 28-day
survival in patients with ARDS compared to conventional treatment (ARDSNet strategy). We will enroll adult
patients with ARDS of less than 72 h duration. The intervention group will receive an alveolar recruitment
maneuver, with stepwise increases of PEEP achieving 45 cmH2O and peak pressure of 60 cmH2O, followed by
ventilation with optimal PEEP titrated according to the static compliance of the respiratory system. In the control
group, mechanical ventilation will follow a conventional protocol (ARDSNet). In both groups, we will use controlled
volume mode with low tidal volumes (4 to 6 mL/kg of predicted body weight) and targeting plateau pressure ≤30
cmH2O. The primary outcome is 28-day survival, and the secondary outcomes are: length of ICU stay; length of
hospital stay; pneumothorax requiring chest tube during first 7 days; barotrauma during first 7 days; mechanical
ventilation-free days from days 1 to 28; ICU, in-hospital, and 6-month survival. ART is an event-guided trial planned
to last until 520 events (deaths within 28 days) are observed. These events allow detection of a hazard ratio of 0.75,
with 90% power and two-tailed type I error of 5%. All analysis will follow the intention-to-treat principle.
Discussion: If the ART strategy with maximum recruitment and PEEP titration improves 28-day survival, this will
represent a notable advance to the care of ARDS patients. Conversely, if the ART strategy is similar or inferior to the
current evidence-based strategy (ARDSNet), this should also change current practice as many institutions routinely
employ recruitment maneuvers and set PEEP levels according to some titration method.
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Acute respiratory distress syndrome (ARDS) is a com-
mon problem in critically-ill patients, associated with in-
hospital mortality between 41% and 58% [1-3] and
reduced quality of life among survivors [4,5]. Although
mechanical ventilation provides essential life support, it
can worsen lung injury [6]. Mechanisms of ventilator-
induced lung injury include regional alveolar overdistention,
repetitive alveolar collapse with shearing (atelectrauma),
and oxygen toxicity [7,8].
Ventilation with low tidal volumes (≤6 mL/kg) and tar-
geting plateau pressures of 30 cmH2O or less improves
survival compared to the use of high volumes (12 mL/kg),
confirming the relevance of avoiding overdistention in
ARDS [9]. Although this strategy improved care of ARDS
patients, mortality is still unacceptably high [3]. Experi-
mental data suggest that atelectrauma is prominent
in ARDS [10,11] and may be a contributor to ARDS
mortality [12]. Opening of collapsed lung tissue by
recruitment maneuvers and preventing further collapse by
using titration of PEEP may prevent atelectrauma. Max-
imum alveolar recruitment followed by PEEP titration is a
relatively simple and widely available intervention.
Some studies demonstrated that maximum recruit-
ment strategy, achieving PEEP of 45 cmH2O and peak
pressure of 60 cmH2O, can fully recruit the lung and re-
verse hypoxemia in most ARDS patients, without major
adverse events [13,14]. However, a systematic review of
alveolar recruitment maneuvers found only four rando-
mized trials and was inconclusive regarding the effect of
recruitment maneuvers on survival and other patients’
relevant outcomes [15]. Recently a pilot study rando-
mized 20 patients to an alveolar recruitment maneuver
with progressive PEEP elevation up to 40 cmH2O and
peak pressure of 55 cmH2O plus PEEP titrated according
to peripheral oxygen saturation or to ARDSNet strategy
[16]. There were a decrease in some systemic cytokines,
and improvement in oxygenation and compliance. As
expected, the trial was not powered to and did not
show any difference in mortality and other clinical
outcomes. Therefore, a trial with high methodological
quality and power to assess whether maximum alveo-
lar recruitment followed by ventilation with titrated
PEEP improves clinical outcomes in ARDS patients is
highly needed.
Methods
Objectives
Our primary objective is to determine if maximum alveolar
recruitment associated with PEEP titrated according to the
static compliance of the respiratory system (ART strategy)
increases 28-day survival rate of patients with acute
respiratory distress syndrome compared to conventional
treatment (ARDSNet strategy).Secondary objectives are to evaluate the effect of the
ART strategy compared to ARDSNet strategy on the fol-
lowing outcomes: length of hospitalization; pneumo-
thorax requiring chest tube at 7 days; barotrauma (any
pneumothorax, pneumomediastinum, subcutaneous em-
physema or pneumatocele >2 cm after randomization) at
7 days; ventilator-free days from days 1 to 28; intensive
care unit, in-hospital, and 6-month survival.
Study design
ART is a randomized, stratified, multicenter trial with al-
location concealment and intention-to-treat analysis.
Patients with ARDS will be treated with a stepwise max-
imum alveolar recruitment maneuver followed by ventila-
tion with optimal PEEP (ART Strategy) vs. a conventional
approach (ARDSNet Strategy). This is an event-guided
trial which will end when 520 events (deaths within
28 days) are observed. Patients will be followed up to
6 months, although the main outcome is determined at
the 28-day follow-up.
Screening
Eligibility will be evaluated in two phases: screening
phase and defining eligibility phase.
In the screening phase, patients will be considered for
inclusion in the study if they are receiving invasive
mechanical ventilation and have ARDS of less than 72 h
duration. All of the following criteria should be met
[17]: acute onset respiratory failure; bilateral pulmonary
infiltrate on chest X-ray compatible with pulmonary
edema; severe hypoxemia, defined as PaO2/FiO2 ≤200 in
arterial blood gases for less than 72 h; absence of left
atrial hypertension based on the medical team’s evalu-
ation (clinical or echocardiographic signs); and presence
of a risk factor for lung injury.
The following are exclusion criteria (exclusion if any one
present): age <18 years; use of vasoconstrictor drugs in
increasing doses over the past 2 h (norepinephrine increase
≥0,5 mcg/kg/min or dopamine increase ≥5 mcg/kg/min)
or mean arterial pressure <65 mmHg; this may be a
transient criterion, since patients meeting this criterion
might be included later if hemodynamics improves;
contraindications to hypercapnia such as intracranial
hypertension or acute coronary syndrome; and undrained
pneumothorax or subcutaneous emphysema.
While waiting for the consent of a legal representative
or for at least 3 h, we suggest to ventilate patients using a
conventional approach as follows [9]: volume-controlled
mode, tidal volume of 4 to 6 mL/kg of predicted body
weight to ensure plateau pressure ≤30 cmH2O, PEEP, and
FiO2 adjusted according to the ARDSNet table (Table 1)
to maintain SpO2 ≥88% and PaO2 ≥55 mmHg, flow of
60 L/min, descending waveform, inspiratory pause of
0.5 s, inspiratory to expiratory ratio (I:E) of 1:1 to 1:2,
Table 1 ARDSNet table of FiO2 and PEEP values to keep SpO2≥ 88% or PaO2≥ 55 mmHg
FiO2 30% 40% 40% 50% 50% 60% 70% 70% 70% 80% 90% 90% 90% 100%
PEEP 5 5 8 8 10 10 10 12 14 14 14 16 18 18-24
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Alveolar recruitment maneuvers should be avoided.
Predicted body weight should be calculated for all
patients according to the formula:
Men : Predicted body weight kgð Þ
¼ 50þ 2:3 height cm½   0:394ð Þ  60ð Þ
Women : Predicted body weight kgð Þ
¼ 45:5þ 2:3 height cm½   0:394ð Þ  60ð Þ
Defining eligibility
Right after obtaining informed consent, ventilator will be
set as described above (if the recommended ventilation
were not set yet) and FiO2 will be adjusted to 100% and
PEEP to 10 cmH2O (except if previous PEEP were ≥16
cmH2O; in this case PEEP will be maintained). Arterial
blood gases will be measured after 30 min.
Patients will be considered eligible if the PaO2 measured
with FiO2=100% and PEEP=10 cmH2O (or ≥16 cmH2O)
is 200 mmHg or less, and less than 72 h have been spent
since the first time a PaO2/FiO2 ≤200 was determined.
Criteria for withdrawal of patients from the trial
The withdrawal of a patient from the study will occur
only if consent is withdrawn by the patient, his/her legal
representative, or the patient’s primary care physician.
Treatment should be discontinued if the patient is suf-
ficiently unstable to contraindicate the continued use of
high PEEP levels. The necessary measures to minimize
instability and adverse effects caused by the use of high
PEEP levels should be implemented as deemed appropri-
ate by the medical team. However, patient follow-up will
proceed normally, that is, the patient will not be
excluded from follow-up and analyses.
Randomization and allocation concealment
Patients will be randomized in a 1:1 ratio to the ART
strategy or the ARDSNet strategy.
The random allocation list was generated in blocks
(number of treatments per block will be kept confiden-
tial to avoid prediction of future patients’ allocation) and
was stratified by investigator center age, and PaO2/FiO2
ratio (≤100 or >100). Allocation concealment will be
maintained by means of a web-based central, automated
randomization system, available 24 h a day (ACT-Clinic),
developed by a team of programmers and investigators
from the Research Institute at Hospital do Coração
(IEP-HCor). The group to which the patient will beallocated will only be disclosed after patient enrollment in-
formation is recorded in the electronic system. This pre-
vents the investigator and the medical team from predicting
to which treatment group the patient will be allocated. To
include a patient in the study, investigators must simply
access the IEP-HCor website (https://servicos.hcor.com.br/
iep/estudoclinico), log in with individual username and
password, and fill in a short medical record form.
Interventions
Table 2 summarizes the procedures that will be used for
ART and ARDSNet groups in this study.
ART strategy (maximum alveolar recruitment maneuver
plus PEEP titration)
If patients are assigned to the ART strategy, the follow-
ing steps should be observed (Figure 1):
1. Preparation for the recruitment maneuver
Patients will be sedated, paralyzed (with a
neuromuscular blocker), and kept in supine position.
Closed endotracheal suction system will be installed.
Monitoring will be provided with at least: heart rate,
cardiac rhythm, periferic oxygen saturation, and
blood pressure (preferably invasive method).
Hypovolemia will be corrected by crystalloid or
colloid infusion until variation of arterial pulse
pressure ≤13%, or central venous pressure of >10
cmH2O if variation of arterial pulse pressure
measurement is not available. If the variation of
arterial pulse pressure method is used, we
recommend to transiently setting tidal volume to
8 mL/kg for 15 min before measurements
2. Maximum alveolar recruitment maneuver
Mechanical ventilator will be set to pressure-
controlled mode with FiO2 of 100%; respiratory rate
of 10/min and I:E ratio of 1:1. Alveolar recruitment
maneuver steps are described below:
 Recruitment starts with PEEP of 25 cmH2O and
driving pressure of 15 cmH2O. These parameters
will be maintained for 1 min;
 Following this, PEEP will be increased to 35 cmH2O
with other parameters maintained for 1 min;
 Lastly, PEEP will be increased to 45 cmH2O with
other parameters maintained for 2 min.
Recruitment will be terminated if one or more of the
following signs of clinical deterioration are observed:
Table 2 Summary of mechanical ventilation procedures in the ART strategy group vs. ARDSNet strategy group
Procedure ART strategy: maximum alveolar recruitment
maneuver associated with PEEP titration
ARDSNet strategy
Alveolar recruitment maneuver Yes (see Figure 1) No
Ventilation mode Volume-controlled Volume-controlled
Target plateau pressure and
driving pressure
Plateau ≤30 cmH2O Plateau ≤30 cmH2O
Target tidal volume 4 to 6 mL/kg of predicted body weight 4 to 6 mL/kg of predicted body weight
Respiratory rate and pH goal 6 to 35/min, adjusted for pH≥ 7.30 if possible 6 to 35/min, adjusted for pH≥ 7.30 if possible
I:E ratio 1:1 to 1:2; flow 60 L/min; inspiratory pause 0.5 s 1:1 to 1:2; flow 60 L/min; inspiratory pause 0.5 s
Oxygenation goals
PaO2 60 to 80 mmHg 55 to 80 mmHg
SpO2 90 to 95% 88 to 95%
PEEP and FiO2 adjustment PEEP titration 2 cmH2O above PEEP value associated
with maximum compliance. FiO2 titration adjusted
according to oxygenation goals
According to PEEP/FiO2 combination table
Weaning After 24 h with PaO2/FiO2≥ 300 (or stable/ascending)
start weaning from PEEP 2 cmH2O every 8 h. Consider
pressure support ventilation after PEEP≤ 14 cmH2O.
Spontaneous ventilation test in PS= 5 cmH2O and
PEEP=5 cmH2O. Routine use of NIV immediately after
extubation is encouraged
Weaning from PEEP according to table of PEEP
and FiO2 combinations. Consider pressure support
ventilation after PEEP≤ 14 cmH2O. Spontaneous
ventilation test in PS= 5 cmH2O and PEEP=5 cmH2O.
Routine use of NIV immediately after extubation is
encouraged
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blood pressure <65 mmHg or decrease of systolic
blood pressure <90 mmHg; decrease of SpO2 <88% for
>30 s; acute atrial fibrilation, atrial flutter or
ventricular tachycardia.
If recruitment is interrupted, physicians should
proceed to PEEP titration, but should not repeat
recruitment after titration (see next section ‘PEEP
titration and new recruitment’). If a patient remainsTime (min
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Figure 1 ART strategy: maximum alveolar recruitment maneuver associaunstable while PEEP is titrated, then PEEP titration
should be interrupted and the patient should be placed
on the ARDSNet protocol. In this case, recruitment
should be considered later if the patient’s condition
stabilizes.3. PEEP titration and new recruitmentu
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predicted body weight, respiratory rate to 20/min,
flow to 30 L/min (square wave) and FiO2 to 100%.
After 4 min, static compliance of the respiratory
system will be calculated and recorded (inspiratory
pause ≥2 s required to reach plateau pressure). In
sequence, PEEP will be decreased in steps of 20, 17,
14, and 11 cmH2O and the corresponding static
compliance of the respiratory system will be
recorded after each 4 min.
Optimal PEEP will be the PEEP associated with the
best static compliance plus 2 cmH2O. If a ‘plateau’ of
best compliance is achieved, that is, more than one
PEEP level associated with the best compliance, then
the higher of the PEEP levels within the ‘plateau’ plus
2 cmH2O is considered the optimal PEEP.
If falls in compliance are verified in two consecutive
steps, the PEEP level with the highest compliance plus
2 cmH2O is the optimal PEEP. In this case, there is no
need to measure compliance on lower PEEP levels.
After the PEEP titration phase, a new alveolar
recruitment will be performed. The mechanical
ventilator will be reset to pressure-controlled mode;
respiratory rate to 10/min; I:E ratio to 1:1, driving
pressure to 15 cmH2O, FiO2 to 100% and PEEP
adjusted to 45 cmH2O. These parameters will be
maintained for 2 min.
4. Maintenance ventilation
Following the new alveolar recruitment, the
maintenance ventilation will be set: volume-
controlled mode, tidal volume of 5 mL/kg of
predicted body weight. If plateau pressure >30
cmH2O, reduce to 4 mL/kg of predicted body
weight. Minimum and maximum tidal volumes are 4
mL/kg and 6 mL/kg of predicted body weight. Flow
of 60 L/min, descending waveform, inspiratory pause
of 0.5 s, I:E ratio of 1:1 to 1:2, respiratory rate to
maintain the same minute ventilation prior to
randomization, PEEP adjusted to optimal PEEP
(PEEP value at maximum compliance plus 2 cmH2O)
and FiO2 adjusted for SpO2 ≥90% and ≤95%.
5. When to repeat a recruitment maneuver
Repetition of the maximum alveolar recruitment
maneuver will be considered only when the initial
maneuver is successful, which we defined as an
increase of PaO2/FiO2 ratio >100 after maneuver.
If the initial maneuver is successful, it will be
repeated in two situations:
 Every 24 h if PaO2/FiO2 ratio is <250 and a
decrease in PaO2/FiO2 ratio >50 occurs. After the
recruitment maneuver, PEEP should be set at thevalue it was before plus 2 cmH2O. That is, there is
no need to titrate PEEP again.
 If an accidental disconnection of the respiratory
circuits occurs and PEEP is ≥12 cmH2O. After the
recruitment maneuver, PEEP should be set at the
same level it was before disconnection. There is
no need to titrate PEEP again.
6. Adjustments in tidal volume and respiratory rate
Adjustments in tidal volume and respiratory rate are
the same for ART group and ARDSNet group, and is
described below.
Respiratory rate and tidal volume must be adjusted
to achieve the arterial pH goal: between 7.30 and
7.45. The pH is measured when clinically indicated.
Management of alkalemia and acidemia
 Alkalemia (pH >7.45): reduce respiratory rate, if
possible
 Mild acidemia (7.15 ≤ pH <7.30):
– If PaCO2 ≤ 40 mmHg, consider sodium bicarbon-
ate and, if possible, treat the cause of metabolic
acidosis
– If PaCO2 > 40 mmHg:
○ Increase respiratory rate up to a maximum of
35 aiming a pH >7.30 or PaCO2 <40 mmHg,
whichever occurs first. If there is associated
metabolic acidosis, it should also be managed.
○ If the respiratory rate =35 and pH is between
7.15 and 7.30, there is no need of additional
measures.
 Severe acidemia (pH <7.15):
 If PaCO2 ≤ 40 mmHg, consider sodium bicarbonate
and, if possible, treat the cause of metabolic acidosis.
 If PaCO2 > 40 mmHg– Increase respiratory rate to 35. If there is
associated metabolic acidosis, it should also be
managed.
– If respiratory rate =35, pH <7.15, and PaCO2
>40 mmHg, increase tidal volume in steps of
1 mL/kg, up to 6 mL/kg of predicted body
weight. In this condition, the plateau pressure
goal of 30 cmH2O can be exceeded.
– If respiratory rate =35, pH <7.15, PaCO2
>40 mmHg, and tidal volume is 6 mL/kg of
predicted body weight, increase tidal volume to
7 mL/kg of predicted body weight.
– If the situation remains unresolved (respiratory
rate =35, pH <7.15, PaCO2 >40 mmHg, and tidal
volume is 7 mL/kg of predicted body weight)
Tabl
Clinic
Objec
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body weight.
7. Refractory hypoxemia
Refractory hypoxemia is defined as a
PaO2 < 55 mmHg or SpO2 < 88% with
FiO2 = 100%. The following sequential actions
should be taken for patients presenting with
refractory hypoxemia:
 Prone position;
 If the patient does not improve, then start
inhaled nitric oxide, if available, beginning with
5 ppm and increasing in steps of 5 ppm until
there is improvement in oxygenation;
 Final step is to initiate extracorporeal
membrane oxygenation (ECMO) if available.
8. Weaning from mechanical ventilation
PEEP weaning can start 24 h after the initial
alveolar recruitment maneuver. PEEP can bee 3 Type of assessment and criteria for performing a spontan
al assessment Improvement of acute process (ARDS and associated
Patient is alert and cooperative
Chest pain is controlled
Adequate cough (moderate to high strength)
Absence of excessive tracheobronchial secretion
No signs of respiratory distress:
Nostril flaring
Use of accessory muscles of respiration (suprasternal a
Paradoxical movements of the chest/abdomen
tive measurements Respiratory stability: oxygenation
PEEP ≤10 cmH2O
Support pressure ≤10 cmH2O
PaO2/FiO2 ≥250 (consider weaning if ≥150)
SpO2 > 90% under FiO2 ≤40%
Respiratory stability: function
Respiratory rate ≤35 breaths/min
Minute volume < 10 L/min
Respiratory rate/tidal volume (L) < 105 breath/min/L
No significant respiratory acidosis (pH ≥7.25)
Cardiovascular stability
Heart rate <140 bpm
Systolic blood pressure > 90 and <160 mmHg
Without vasoconstrictor/inotropic drugs (or low doses
Neurological stability
Patient alert and cooperative - SAS 4 (acceptable: slighdecreased 2 cmH2O each 8 h as long as the PaO2/
FiO2 ratio are >300. In case of not achieving PaO2/
FiO2 ratio >300 after alveolar recruitment, PEEP
can be decreased 2 cmH2O each 8 h if PaO2/FiO2
ratio is similar or greater than the day before.
Other than the PEEP weaning procedure described
above, the rest of the weaning method is equal in
the ART and ARDSNet groups, and is described
below.
Pressure support (PS) ventilation can be initiated
in alert patients when PEEP ≤14 cmH2O. Start
with PS of 10 cmH2O or less to achieve tidal
volume of 6 mL/kg of predicted body weight. PS
ventilation can be reduced from 2 to 4 cmH2O
twice daily as long as respiratory frequency is <28
breaths per min (and there are no other signs of
discomfort). In patients with signs of discomfort
(for example, those with ≥30 breaths per minute)
investigators should consider other causes (such
as pain or anxiety) before increasing PS. If PS over
14 cmH2O is needed, then volume-controlled
ventilation will be resumed.eous breathing test
conditions) leading to intubation and mechanical ventilation
nd/or intercostal retraction)
)
tly drowsy patient (SAS 3) slightly agitated (SAS 5))
Tabl
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breathing test will be performed preferably during
the morning. The criteria shown on Table 3 will be
considered to start the spontaneous breathing test.
Spontaneous ventilation test will be performed
using PS mode, with PEEP of 5 cmH2O, PS of 5
cmH2O, for 30 min. Criteria to diagnose failure in
spontaneous ventilation test are presented in
Table 4.
Patients who pass the spontaneous breathing test can
be extubated. Cuff leak test is optional. Systemic
steroids for patients intubated for long periods, with
the aim to prevent upper airway obstruction after
extubation, are also optional. Non-invasive ventilation
should be considered for all patients. This is strongly
recommended for patients at high risk of extubation
failure, such as: patients who do not meet all the
criteria for extubation (for example, respiratory rate/
tidal volume (L) ≥105 breaths/min/L); and patients
who failed the spontaneous breathing test at least
once.ARDSNet strategy (conventional ventilation)
1. Maintenance ventilation
If patients are assigned to the ARDSNet strategy, no
alveolar recruitment will be performed. The
conventional mechanical ventilation strategy that will bee 4 Type of assessment and criteria for failure of the spont
al assessment Agitation, ex
Major sweatin
Cyanosis
Signs of respi
Nostril flari
Use of acce
Paradoxica
tive measurements Respiratory in
SpO2 < 90%
Respiratory in
Respiratory
Respiratory
If arterial b
pH <7.25
PaCO2 >
Cardiovascula
Heart rate
Systolic blo
Onset of arused in this group has been described previously [9,18].
Initial ventilator settings will be:
 Volume-controlled mode;
 Plateau pressure ≤30 cmH2O;
 Tidal volume of 5 mL/kg of predicted body
weight. If plateau pressure >30 cmH2O, reduce
to 4 mL/kg of predicted body weight.
Minimum and maximum tidal volumes are
4 mL/kg and 6 mL/kg of predicted body
weight;
 Respiratory rate will be adjusted with the aim of
maintaining the same minute volume recorded
before study entry. Maximum respiratory rate will
be 35/min;
 Flow 60 L/min;
 Descending inspiratory flow;
 Inspiratory pause 0.5 s;
 I:E ratio between 1:1 a 1:2;
 PEEP and FiO2 adjusted according to the
ARDSNet (Table 1) aiming to keep the
oxygenation goals: SpO2 between 88% and 95%,
and PaO2 between 55 mmHg and 80 mmHg.
2. Adjustments in tidal volume and respiratory rate
These are the same as described for the ART Group
above.
3. Refractory hypoxemiaaneous breathing test
cessive anxiety, or depressed level of consciousness
g
ratory distress:
ng
ssory muscles of respiration (suprasternal and/or intercostal retraction)
l movements of the chest/abdomen
stability: oxygenation
stability: function
rate > 35 breaths/min or increase >10 breaths/min
rate/tidal volume (L) <105 breath/min/L
lood gases measured:
50 mmHg or increase >8 mmHg
r instability
<140 bpm
od pressure < 90 and >160 mmHg
rhythmias (for example, frequent ventricular extrasystole)
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for the ART group, that is, a PaO2 < 55 mmHg or
SpO2 < 88% with FiO2 = 100%.
The sequence of actions to be taken for patients
presenting with refractory hypoxemia is similar,
except for the first two steps, as is describe below:
 Increase PEEP up to 24 cmH2O and FiO2 to 100%
(as in the right end of the ARDSNet table
(Table 1));
 If no improvement is achieved, than PEEP should
be increased 2 to 5 cmH2O each step up to 34
cmH2O or until PaO2 is between 55 mmHg and
80 mmHg or SpO2 is 88%; to 95%.
 If no improvement is achieved, PEEP should be
lowered to 24 cmH2O, and the sequence
described above to manage refractory hypoxemia
in the ART group should be followed. First step, is
to put the patient in the prone position;
 If the patient does not improve, then start inhaled
nitric oxide, if available, beginning with 5 ppm
and increasing in steps of 5 ppm until there is
improvement in oxygenation;
 Final step is to initiate ECMO if available.
4. Weaning from mechanical ventilation
Weaning of PEEP and FiO2 is done following the
ARDSNet table (Table 1).
Other aspects of weaning are the same as described
above for the ART group.Blinding
Since the intervention will be administered to critically-
ill patients on mechanical ventilation (that is, mostly
sedated), blinding of these patients is not necessary. Be-
cause this is a non-pharmacological intervention, blind-
ing of the medical team is not feasible. There is no need
for a committee to validate the primary study outcome
(28-day survival), and therefore outcome adjudicators
will not be blinded.Outcomes
The primary outcome of the ART is 28-day survival.
The secondary outcomes are: (1) length of ICU stay; (2)
length of hospital stay; (3) pneumothorax requiring chest
tube at 7 days; (4) barotrauma (any pneumothorax,
pneumomediastinum, subcutaneous emphysema, or
pneumatocele > 2 cm after randomization) at 7 days; (5)
mechanical ventilation-free from days 1 to 28; (6) ICU
survival; (7) in-hospital survival; and (8) 6-month
survival.Data collection and management
Study follow-up and the variables that will be collected
are described below.
Screening and eligibility data (Day 0)
 Patient’s initials, gender, date of birth
 Verification of ARDS criteria
 Screening inclusion and exclusion criteria
 Respiratory variables (tidal volume, plateau pressure,
total respiratory rate, PEEP, FiO2) while awaiting
informed consent
 Final eligibility criteria:
 PaO2 at FiO2 of 100% and PEEP of 10cmH2O
(or greater if previous PEEP were ≥16cmH2O)
 Estimated time from onset of ARDS (onset of
ARDS based on arterial blood gases until
randomization)
Baseline Data (Day 0)
The following data will be recorded at the baseline visit:
 Weight (measures with a weighing scale)
 Height
 SAPS 3 (at ICU admission)
 Respiratory variables (Tidal volume, Plateau
pressure, Total respiratory rate, PEEP, FiO2)
 Sequential organ failure assessment (SOFA)
 Cause of ARDS
 Days of intubation prior randomization
Treatment Data (1 h after start of intervention)
The following data regarding treatment will be assessed
for patients randomized to ART strategy:
 Alveolar recruitment (for the group treated with
maximum alveolar recruitment)
 Maximum PEEP reached
 If maximum alveolar recruitment is interrupted, the
reason provided (list of criteria for interruption)
 The following data regarding treatment will be
assessed for all patients:
 Respiratory variables of maintenance ventilation
(Tidal volume, Plateau pressure, Total respiratory
rate, PEEP, FiO2, PaO2, PaCO2, Arterial pH)
 Hemodynamic variables (Heart rate, Mean blood
pressure, Use of noradrenaline and dopamine)
1-Day Follow-Up
 Respiratory variables of maintenance ventilation
(Tidal volume, Plateau pressure, Total respiratory
rate, PEEP, FiO2, PaO2, PaCO2, Arterial pH)
 Water balance and weight (weighing scale)
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 Respiratory variables of maintenance ventilation
(Tidal volume, Plateau pressure, Total respiratory
rate, PEEP, FiO2, PaO2, PaCO2, Arterial pH)
 Water balance and weight (weighing scale)
7-day follow-up
 Vital status at day 7. If patient dies before day 7, the
following variables should be collected:
 Date of death
 Death due to refractory hypoxemia
 Death due to refractory respiratory acidosis
 Death due to refractory barotrauma
 Number of days on mechanical ventilation
 Respiratory variables of maintenance ventilation
(Tidal volume, plateau pressure, total respiratory
rate, PEEP, FiO2, PaO2, PaCO2, arterial pH)
 Water balance and weight (weighing scale)
 Co-interventions during the period (use of/
number of days using neuromuscular blockers;
use of/number of days using continuous infusion
of sedatives; use of/number of days using
continuous infusion of narcotics; use of/number
of days using noradrenaline or dopamine; use of/
number of days using corticoids; rescue therapies
for refractory hypoxemia: prone position, nitric
oxide, high frequency oscillatory ventilation,
ECMO)
 Pneumothorax requiring chest tube drainage during
the period
 Barotrauma (any pneumothorax,
pneumomediastinum, subcutaneous emphysema, or
pneumatocele > 2 cm after randomization) during
the period
Hospital discharge
 Date of ICU discharge and vital status at ICU
discharge
 Date of hospital discharge and vital status at hospital
discharge
28-day follow-up
 Days on mechanical ventilation (considering the first
28 days after randomization)
 Vital status and date of death (for patients who died)
6-month follow-up
 Vital status and date of death (for patients who died)Clinical Data Management System (CDMS) and quality
control
Besides the 24-h concealed randomization, the ACT Clinic
will provide data entry, data cleaning, and exportation for
analysis. The system will also provide reports on the status
of the study forms (completed forms, overdue forms),
weekly study recruitment by center, and graphs of
observed and expected cumulative recruitment.
Several procedures will assure data quality, including:
(1) all investigators will attend a training session before
the start of the study to standardize procedures, includ-
ing data collection; (2) the investigators may contact the
Study Coordinating Center to solve issues or problems
that may arise; (3) data entry into the ACT-Clinic is
subject to various checks for missing data, plausible,
possible or non-permitted value ranges, and logic checks.
Problems are informed by the system at the time of data
entry; (4) statistical techniques to identify inconsistencies
will be applied periodically (about every two weeks). The
centers will be notified of the inconsistencies and asked to
correct them; (5) statistical routines to identify fraud will
be conducted periodically (every 90 days); (6) on-site
monitoring will be conducted during study conduction;
(7) the coordinating center will review detailed reports on
screening, enrolment, follow-up, inconsistencies, and
completeness of data. Immediate actions will follow to
solve problems that arise.
Sample size
ART is an event driven study designed to last until 520
events (deaths within 28 days) are observed. This num-
ber of events is sufficient to detect a hazard ratio of 0.75
(that is, relative reduction in event rate of 25%), consid-
ering a type I error of 5%, 90% power, and a similar allo-
cation of subjects to each group. Considering an event
rate in the control group of 36% (mean proportion of
deaths in randomized studies conducted after 1994,
when the definition of ARDS was first standardized) [3]
we expect that about 1,620 patients will be needed to
achieve the number of events planned. However, since
this is an event driven study, the total sample size can
vary depending on the event rate in the experimental
and control groups.
Statistical analysis plan
All analysis will follow the intention-to-treat principle.
Survival within 28 days (primary outcome) in both
groups will be assessed using Kaplan-Meier curves and
Cox proportional hazard models, without adjustment
for other co-variates. Treatment effects on length of
ICU stay, hospital stay, and number of mechanical
ventilation-free days at 28 days will be analyzed using
Mann–Whitney tests. Occurrence of pneumothorax and
barotrauma will be evaluated using chi-square tests; ICU
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square tests; 6-month survival will be analyzed using
Kaplan-Meier curves and Cox proportional hazards
models. Treatment effect on 28-day survival will be
analyzed in the following subgroups: (1) PaO2/FiO2 ≤100
vs. >100; (2) SAPS 3 score <50 vs. ≥50; 3) (pulmonary
ARDS (pneumonia, aspiration, pulmonary contusion, near
drowning) vs. extrapulmonary ARDS (non-pulmonary
sepsis, trauma without pulmonary contusion, major
surgery, multiple transfusions, traumatic brain injury,
drug overdose, shock, other cause) (4) time of ARDS
≤36 h vs. >36 to <72 h; (5) mechanical ventilation
≤2 days, 3 to 4 days, ≥5 days. Effects on subgroups will
be evaluated using the chi-square test for homogen-
eity. Statistical significance is defined as P < 0.05. All
analyses will be carried out using the statistical soft-
ware R (R Development Core Team, URL http://www.
R-project.org - version 2.13) or STATA SE 11 for Windows
(College Station, TX, USA).
Ethical aspects
Each investigator center will submit the study protocol
to its institutional Research Ethics Board (REB). The
study should start only after being approved by the
REB. Written informed consent will be obtained
from a legal representative of all participants. This
study is in compliance with Brazilian and international
declarations.
Trial organization and management
Trial management team (TMT)
A team based on the Research Institute HCor, São Paulo,
Brazil will manage the trial on a day-to-day basis. The
TMT is comprised by the chief investigator, a project
manager, a statistician, and a computer programmer.
The responsibilities of the TMT include:
 Planning and conducting the study: designing the
protocol; designing the electronic case report forms
(e-CRF); designing the operation guide; managing
and controlling data quality; designing, testing, and
maintaining the electronic data capture system;
continuous data quality control; assisting the
steering committee;
 Managing the research centers: selecting and
training the research centers; helping the centers
prepare a regulatory report to be submitted to the
REBs and assisting the centers with the submission;
monitoring recruitment rates and the actions to
increase recruitment; monitoring follow-up and
implementing actions to prevent follow-up losses;
auditing; sending study materials to the research
centers; producing a monthly study newsletter;
developing supporting material for the study; Statistical analysis and research reporting: complete
statistical analysis; helping to write the final manuscript.
Trial steering committee (TSC)
The TSC is responsible for the overall study supervision,
assisting in developing the study protocol and preparing
the final manuscript. All other study committees report
to the TSC. The TSC members are investigators trained
in designing and conducting randomized clinical trials,
intensivists, respiratory therapists, and pulmonologists
experienced in conducting multicenter randomized stud-
ies on ARDS.
Trial centers
Initially 80 centers would be invited to participate in the
study, but the current goal is to involve 120 centers in
the study. Details of the centers which accepted to par-
ticipate in the trial at the time of this manuscript sub-
mission are given in the Appendix.
Institutional support from the Brazilian Association of
Intensive Care Medicine (Associação de Medicina Intensiva
Brasileira (AMIB))
The AMIB supports the ART study by means of the
AMIB-Net. The AMIB-Net will assist with the selection
and invitation of centers to participate in the ART, as
well as facilitate the organization of meetings of
researchers during national scientific meetings organized
by the AMIB.
Publication policy
The ART study success depends on all its collaborators.
Therefore, the primary results of the trial will be pub-
lished under the name of ART Investigators. The contri-
butions of all collaborators, their names and respective
institutions, will be acknowledged in the manuscript. To
safeguard the scientific integrity of the study, data from
this study will be submitted to publication only after the
final approval from the TSC.
Data monitoring committee (DMC)
The DMC is set up with independent epidemiologists
and intensivists. The DMC is in charge of providing
recommendations for the TSC of continuing the study
as planned or discontinuing the recruitment based on
evidence that the intervention causes increased mortality
in the experimental group as compared to the control
group. Interim analyses will be conducted after recruit-
ment of approximately 33% and 66% of the sample.
Based on these interim analyses, and, occasionally, on
external evidence, the DMC shall decide whether there
is evidence beyond a reasonable doubt that the treat-
ment is clearly contraindicated in all patients or any sub-
group. The criterion of evidence beyond a reasonable
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imum lung recruitment strategy compared with the low
PEEP strategy, with P <0.01. Otherwise, the TSC and
other investigators will not be informed of the results of
interim analyses. Considering previous evidence showing
that: (1) early discontinuation of randomized trials due
to benefits tends to produce biased estimates of effect
(overestimation of the true effect), leading to erroneous
medical guidelines and decisions [19]; (2) according
to the ethical principle of non-maleficence, a new
treatment should not be used until there is clear,
objective evidence that it is beneficial; (3) clinical
practice usually does not change unless there is fairly
convincing evidence of the advantages of the new
treatment, which would be undermined if the study is
discontinued early due to benefits; the decision of
early discontinuation of the experimental treatment
due to benefits may not be advantageous for future
patients, or may contribute to mislead guidelines
[20]. For these reasons, early discontinuation of the
study due to benefits of the experimental treatment is
not planned.
Discussion
ARDS is a common problem in intensive care associated
with a very large in-hospital mortality rate, in spite of
advances in therapy [3]. Maximum alveolar recruitment
followed by PEEP titration is a relatively simple, inex-
pensive, and widely available intervention with potential
to improve the prognosis of patients with ARDS. In
most patients with ARDS, this strategy is able to keep
open more than 90% of lung mass, improving oxygen-
ation and preventing atelectrauma [13]. However, the
effects of this strategy on patient important outcomes
remain to be established. Therefore, evidence from well
designed and conducted trials to solve this question is
essential.
The ART was planned to be the largest randomized
trial involving ARDS patients conducted to date. It will
provide a precise and reliable estimate of the effect of al-
veolar recruitment and PEEP titration on survival of
ARDS patients compared to the ARDSNet strategy, cur-
rently the evidence-based best approach for mechanical
ventilation.
If our study finds that the maximum alveolar recruit-
ment plus PEEP titration is not beneficial, this will play a
role in changing medical practice since maximum alveo-
lar recruitment associated with high levels of PEEP is
routinely used by many intensivists. On the other hand,
if the study demonstrates that maximum alveolar
recruitment associated with PEEP titration increases
survival in patients with ARDS, this will represent a
valuable improvement for the treatment of ARDS
patients.Trial status
The ART is currently ongoing in 103 sites in Brazil,
Colombia, Italy, and Mexico. Enrollment started in
December 2011 in one site. Now, 40 sites are actively
screening for patients, and the remaining are undergoing
REB evaluation. As of June 1, 2012, we had already
enrolled 63 patients. We are inviting centers in other
countries to join us.
Appendix
The ART Investigators consists of:
Writing and Steering Committee: Alexandre B. Cavalcanti
(Co-Chair), Otávio Berwanger, Érica A Suzumura, Marcelo
BP Amato, Fernando S Tallo, Ederlon AC Rezende, José
MM Telles, Edson Romano, Hélio P Guimarães, Marisa M
Regenga, Luzia N Takahashi, Cassiano Teixeira, Roselaine P
Oliveira, Vitor O Carvalho, Fredi A Díaz-Quijano, Carlos
RR Carvalho (Co-Chair and Senior Investigator).
Trial Management Team: Alexandre B Cavalcanti,
Érica A Suzumura, Otávio Berwanger, Alessandra A
Kodama, Gisele FM Ribeiro, Matheus O Abreu, Ivonaldo
M Oliveira.
Data Monitoring Committee: Gordon Guyatt (Chair),
Niall Ferguson, Stephen Walter.
Trial centers: Brazil: Hospital de Urgências e Emergên-
cias de Rio Branco–HUERB, Rio Branco-AC: Márcia O.
M. Vasconcelos, Valério J. Segundo, Íris L. Ferraz, Rosicley
S. Silva; Hospital e Pronto-Socorro 28 de Agosto, Manaus-
AM: Wilson de Oliveira Filho, Nelson B. Silva, Débora
C. B. Heirel, Rodrigo R. Takatani, Jefferson A. Sousa
Neto, Jerônimo C. B. Neto, Samara D. Almeida, Gauco
Chamy; UNIMED Manaus, Manaus-AM: Wilson de
Oliveira Filho, Graciliano J. L. Gonçalves Neto, Samara D.
Almeida, Alysson P. Dias, Rozangela R. Silva; Fundação
Hospital Adriano Jorge, Manaus-AM: Roberta C. Tavares,
Márcia L. V. D. Souza, Janaína C. Decio; Hospital Santa
Izabel - Santa Casa de Misericórdia da Bahia, Salvador-
BA: Cyntia M. L. S. Lima, Fleury Ferreira Neto; Hospital
Regional de Juazeiro - Gestão IMIP, Juazeiro-BA: Kátia R.
Oliveira, Polyana P. L. C. Dias, André L. S. B. Brandão,
Joroastro E. Ramos Jr, Paula T. Vasconcelos; Hospital Uni-
versitário Prof. Edgar Santos, Salvador-BA: Dimitri G.
Flôres, Gilvan R. Pinheiro Filho, Isaac G. Andrade; Hos-
pital Espanhol, Salvador-BA: Amadeu Martinez, Gustavo
G. P. França, Lívia L. Monteiro, Emmanuel I. S. Correia,
Wagner Ribeiro, Antonio J. Pereira, Wandalvo Andrade,
Petrônio A. Leite, Gilvan R. Pinheiro Filho; Hospital Geral
Roberto Santos, Salvador-BA: Dimitri G. Flôres; Hospital
de Messejana, Fortaleza-CE: José E. Filgueira Feto,
Marcelo A. Holanda; Hospital Regional de Samambaia,
Brasilia-DF: Fábio F. Amorim, Silviano B. Margalho; Hos-
pital Regional da Asa Norte - HRAN, Brasilia-DF: Sergio
M. Domingues Jr, Claiton S. Ferreira, Cassia M. Ferreira,
Livia A. Rabelo, Juliana N. Duarte, Fernando B. Lima, Inês
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http://www.trialsjournal.com/content/13/1/153A. L. Kawaguchi; Hospital Santa Luzia, Brasilia-DF: José
A. Araújo Neto, Marcelo O. Maia; Hospital Santa Lucia,
Brasilia-DF: Fabiano G. Correa; Hospital Anchieta,
Brasilia-DF: Rubens A. B. Ribeiro; Centro Integrado de
Atenção à Saúde – CIAS, Vitória-ES: Eliana Caser,
Cora L. C. B. Moreira, Antonielen Marcilino, Jansen
G. Falcão, Karinne R. Jesus, Leo Tcherniakovisk, Victor G.
Dutra; Hospital Evangélico de Cachoeiro de Itapemirin,
Cachoeiro de Itapemirim-ES: Marlus M. Thompson;
Vitória Apart Hospital, Vitória-ES: Claudio Piras, Jonas
Giuberti Jr, Albano S. Silva; Vila Velha Hospital, Vila
Velha-ES: José R. P. Santos, Jorge L. Potratz, Ludmila N.
Paula, Giovana G. Bozi, Bruno C. Gomes; Hospital das
Clínicas - UFES, Vitória-ES: Paula F. Vassallo, Edson
P. Rocha, Maria H. B. S. Lima; Hospital das Clínicas
(UFG), Goiania-GO: Denise M. Ferreira, Fernanda A.
F. Gonçalves, Sheila A. Pereira, Marciano S. Nobrega,
Carlos R. Caixeta; Hospital Geral Tarquínio Lopes
Filho, São Luiz-MA: Ana P. P. Moraes; UDI Hospital,
São Luiz-MA: Alexandre G. R. Carvalho; Santa Casa
da Misericórdia de Ouro Preto, Ouro Preto-MG: Janine D.
Alves; Hospital Eduardo de Menezes, Belo Horizonte-MG:
Frederico B. Carvalho, Fabiana B. R. Moreira, Claudia M.
Starling, Wivian A. D. Couto; Fundação Hospitalar São
Sebastião, Tres Corações-MG: Wesley S. Bitencourt;
Hospital Cônego Monte Raso, Baependi-MG: Wesley
S. Bitencourt; Hospital Municipal Odilon Behrens, Belo
Horizonte-MG: Frederico B. Carvalho, Daniela C. Peixoto,
Ivana L. V. Carvalho, Silvângela G. A. Silva, Livia R. S. M.
Felizardo, Francine J. Magalhães Nascimento, Priscila J. C.
D. Santos, Camila C. Zanta, Marcele F. Martins; Hospital
São Lucas de Governador Valadares, Governador Valadares-
MG: Sérgio A. Naves, Fabiano D. Silva, Gilberto Laube
Jr; Santa Casa de Caridade de Diamantina, Diamantina,
MG: Endi L. Galvão, Marcelo F. Sousa, Marcia M. F. Souza,
Fernanda L. G. Carvalho; Hospital Santa Lúcia - Hospital
do Coração de Poços de Caldas, Poços de Caldas-MG:
Ricardo R. Bergo; Hospital Regional de Mato Grosso do
Sul Rosa Pedrossian, Campo Grande-MS: Claudnei M.
Rezende, Edys Y. Tamazato, Saturnino Campo Sarat Jr,
Patrícia S. Almeida, Anthony G. Gorski; Hospital Uni-
versitário - Universidade Federal da Grande Dourados,
Dourados-MS: Mirna Matsui, Ervin Eberhart Neto,
Silmara H. Nomoto, Zildamara B. Lima, Alexandre S.
Inagaki, Fernando S. U. Gil, Mario F. A. Araújo, Aline
E. Oliveira, Tiago A. Correa, Angela Mendonça; Hos-
pital de Clínicas Gaspar Vianna, Belém-PA: Helder
Reis, Saul R. Carneiro; Carlos Castanelo, Edward
Coelho Jr, Karine A. E. H. Amaral; Hospital Saúde da
Mulher, Belém-PA: Leila R. M. Rego, Adenard F. C.
Cunha, Williams F. Barra, Maurício Carneiro, Roseane
A. Batista, Karina K. Zoghbi; Fundação Santa Casa de
Misericórdia do Pará, Belém, PA: Nelma J. N. Machado,
Reinaldo Ferreira, Pablo Apoena, Rosangela M. Leão;Hospital de Emergência Trauma Senador Humberto
Lucena, João Pessoa-PB: Eliauria R. Martins, Marcelo E.
Oliveira, Isaura Odir, Wladimy Kleber, Daniele Tavares;
Hospital UNIMED João Pessoa, João Pessoa-PB:
Eliauria R. Martins, Marcelo E. U. Araújo, Yuzeth
Nóbrega Brilhante, Daniele C. C. Tavares, Wladmy Kleber,
Waneska L. N. Carvalho, Geórgia F. P. Winveler; Hospital
Alfa, Recife-PE: Aldir Chagas Filho, Raphael Ali Caval-
canti; Hospital Evangélico de Londrina, Londrina-PR:
Cintia M. C. Grion, Andrezza T. J. B. Reis, Josiane Festti,
Francielli M. P. Gimenez; Hospital Universitário Regional
do Norte do Paraná, Londrina-PR: Cintia M. C. Grion,
Alexandre S. Larangeira, Lucienne T. Q. Cardoso, Ana L.
Mezzaroba, Thiago S. Giancursi, Ivanil A. M. Kauss; Hos-
pital São Lucas/FAG, Cascavel-PR: Péricles A. D. Duarte,
Tatiane C. Tozo, Priscila Peliser; Hospital Universitário
Regional de Maringá, Maringá-PR: Almir Germano,
Sanderland J. T. Gurgel, Sandra R. B. Silva, Cristina M
Kuroda, Andrea Herek, Sergio S. Yamada; Hospital Santa
Casa - Campo Mourão, Campo Mourão-PR: Paulo M.
Schiavetto; Hospital Santa Tereza de Guarapuava,
Guarapuava-PR: Natacha Wysocki, Rosely R. Matsubara;
Hospital de Clínicas de Padre Miguel, Rio de Janeiro-RJ:
João A. L. Sales Jr, Maria P. Laprovita; Hospital Prontocar-
dio, Campos dos Goytacazes-RJ: Felipe M. Pena, Alexandre
Sá; Clínica São Vicente, Rio de Janeiro-RJ: Arthur Vianna;
Hospital Barra D’Or, Rio de Janeiro-RJ: Juan C. Verdeal,
Glória A. Martins, Diamantino R. Salgado; Hospital Monte
Sinai, Ariquemes-RO: Adalberto M. Coelho, Milena P. P.
M. Coelho, Aline S. Morong, Rodolfo M. B. Poquiriqui,
Ana P. Ferreira, Debora N. L. Lucena, Nathalia F. Marino,
Monique A. Moreira, Cristiana C. S. Uratani; Hospital
Estadual e Pronto Socorro João Paulo II, Porto Velho –
RO: Marta A. Severino, Patrícia N. Silva, Luciana G.
Medeiros, Francisco G. Chaves Filho, Daniela M. Q. S.
Guimarães; Hospital Geral de Roraima, Boa Vista-RR:
Valéria M. C. Rezende, Roberto C. C. Carbonell, Renata S.
Trindade; Hospital Nossa Senhora da Conceição, Porto
Alegre-RS: José A. S. Pellegrini, Márcio M. Boniatti,
Moreno C. Santos, Rodrigo Boldo, Vanessa M. Oliveira,
Viviane M. Corrêa, Wagner Nedel; Hospital Moinhos de
Vento, Porto Alegre-RS: Cassiano Teixeira, Roselaine
P. Oliveira, Felipe Schaich, Luciana Tagliari, Augusto
Savi, Luis F. Schulz, Juçara G. Maccari; UTI Central -
Irmandade Santa Casa de Misericórdia de Porto Alegre,
Porto Alegre-RS: Roselaine P. Oliveira, Cassiano Teixeira,
Gabriela M. Seeger, Rafael B. Foernges, Marcelo M. Rieder,
Daniel A. Becker, Fabiano P. Broilo; UTI do Pavilhão
Pereira Filho - Santa Casa de Misericórdia de Porto Ale-
gre, Porto Alegre-RS: Patrícia Schwarz, André Alencastro,
Paula Berto, Fabiane Backes, José A. S. Pellegrini; Hospital
São Lucas da PUCRS, Porto Alegre-RS: Fernando S. Dias,
Clarissa Blattner, Edna T. J. Martins, Nóris C. Scaglia;
Hospital de Clínicas de Porto Alegre (HCPA), Porto
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http://www.trialsjournal.com/content/13/1/153Alegre-RS: Silvia R. R. Vieira, Karen F. Prado, Lea
Fialkow, Cristiano Franke, Debora F. V. B. Vieira, Rafael B
Moraes, Patrícia Schwarz, Leonardo S. Marques, João L. S.
Hopf, Iuri C. Wawrzeniak, Tatiana H. Rech, Régis B.
Albuquerque; Hospital Universitário São Francisco de
Paula, Pelotas-RS: Márcio O. Guerreiro, Luciano O.
Teixeira, Pedro L. Macedo, Marina P. Bainy, Edgard V.
Ferreira; Hospital do Coração - Balneário de Camboriu-
SC: Marcio A. Martins, Luciana A. S. Andrade; Hospital
Universitário - UFSC, Florianópolis-SC: Fernando O.
Machado; Hospital Nereu Ramos, Florianópolis-SC: Ana
C. Burigo, Mariangela Pincelli, Lara Kretzer, Israel S. Maia;
Hospital UNIMED Joinville, Joinville-SC: Rodrigo B.
Cordeiro, Glauco Westphal, Milton Caldeira, Amanda
S. Cramer, Michelli M. Dadam, Pierry O. Barbosa; Hospital
São José, Joinville-SC: Milton Caldeira, Glauco Westphal,
Caroline O. Brilenger, Marina B. W. Horner, Glauce
L. Oliveira, Bruno C. Germiniani, Cristina Teixeira, Robson
Duarte; Hospital Regional Hans Dieter Schmidt, Joinville-
SC: Maria G. P. L. Assef, Deorgelis Rosso, Rodrigo Bigolin,
Raquel Vanzuita; Associação Hospitalar e Maternidade
Cônsul Carlos Renaux, Brusque-SC: Márcio A. Martins;
Hospital Primavera, Aracaju-SE: Luiz F. A. Prado, André L.
V. Oliveira, Diego L. Reis, Mirene O. Morais, Rafael S.
Bastos, Hericalizandra S. R. Santana, Alline O. Silva, Lucas
A. P. Cacau, Marília S. Almeida; Hospital de Urgência de
Sergipe - HUSE, Aracaju-SE: Hugo Schlebinger Canavessi,
Eduardo E. F. Nogueira, Caio L. P. Pavia, Diego L. Reis,
José F. Araujo, José A. Lira, Esteban C. Nienstedt, Thiago
C. Smith; Hospital do Coração - HCor, São Paulo-SP:
Edson Romano, Marcelo Romano; Marisa M. Regenga,
Dalton Barros, André F. Costa, Luzia Takahashi, Vinicius
Werneck, Jorge Farran, Lilian A. Henriques, Claudia
Miura; UTI da Clínica Médica - Hospital São Paulo –
UNIFESP, São Paulo-SP: Renato D. Lopes, Letícia S.
Vendrame, Hélio P. Guimarães, Priscila Sandri, Marcela S.
Galassi; UTI Respiratória - Hospital das Clínicas da
FMUSP, São Paulo-SP: Carlos R. R. Carvalho, Marcelo B.
P. Amato, Carlos Toufen Jr, Roberta R. S. Santiago,
Adriana S. Hirota; UTI Clínica - Hospital das Clínicas
da FMUSP, São Paulo-SP: Marcelo Park, Luciano C.
P. Azevedo; UAC I e UAC II - Hospital das Clínicas
da FMUSP, São Paulo-SP: Luiz M. Malbouison; UTI
da Nefrologia - Hospital das Clínicas da FMUSP, São
Paulo-SP: Maristela C. Costa; UTI Clínica do Pronto
Socorro - Hospital das Clínicas da FMUSP, São Paulo-SP:
Leandro Taniguchi; UTI Cirúrgica - Hospital das Clínicas
da FMUSP, São Paulo-SP: Carlos E. Pompílio; Hospital
Moyses Deutsch (M’Boi Mirim), São Paulo-SP: Claudio
Baruzzi, Ana H. V. Andrade, Elisabete E. Taira, Bruno
Taino, Clezio S. Oliveira, Anselmo C. Silva; Hospital do
Servidor Público Estadual, São Paulo-SP: Alexandre
Ísola, Ederlon Rezende, Ricardo G. Rodrigues, Vivian P.
L. Rangel, Sergio Luzzi, Ivens W. S.Giacomassi; Hospital eMaternidade São Camilo - Unidade Pompeia, São Paulo-
SP: Antonio P. Nassar Jr, Ana R. Souza; Hospital São Luiz -
Unidade Itaim, São Paulo-SP: Luciana Rahal, Andre L.
Nunes, Fabio Giannini, Brena Menescal, Jussara E. P.
Morais, Diogo Toledo; Hospital São Luiz - Unidade Anália
Franco, São Paulo-SP: Rafaela D. Morsch, Thalita
Merluzzi, Denise S. Amorim, Ana C. A. G. Bastos, Patrícia
L. Santos, Sabrina F. Silva, Raquel C. N. Gallego, Gheisa
D. Santos; AC Camargo, São Paulo-SP: Mauro Tucci,
Ramon T. Costa, Lucio S. Santos, Sergio E. Demarzo;
Hospital Sírio Libanês, São Paulo-SP: Guilherme P. P.
Schettino, Luciano C. P. Azevedo, Vivian C. Suzuki, Ana
C. L. Patrocinio, Mariana L. Martins, Denise B. V. G.
Passos; Hospital da Luz, São Paulo-SP: Sylas B. Cappi;
Hospital SãoLuiz - Unidade Morumbi, São Paulo-SP:
Iran Gonçalves Jr; HCRP-FMRP-USP, Ribeirão Preto-SP:
Marcos C. Borges, Wilson Lovato, Marcel V. Tavares,
Daniela Morales, Luis A. M. W. Machado, Franciele C. C.
Torres, Tania M. Gomes, Rodrigo B. Cerantola; UTI
do Pronto Socorro - Hospital São Paulo - UNIFESP,
São Paulo-SP: Aécio Góis, Thiago Marraccini; Kathia
Margarida, Eulália Cavalcante; UTI Anestesiologia -
Hospital São Paulo -UNIFESP, São Paulo-SP: Flávia
R. Machado, Bruno F. Mazza, Heloisa B. Rossetti Santana,
Vanessa M. F. Mendez, Patricia A. Xavier, Melina V.
Rabelo, Fabiana R. Schievano, Walkyria A. M. Pinto,
Renata S. Francisco, Elaine M. Ferreira; Instituto de Onco-
logia Pediátrica GRAACC - UNIFESP, São Paulo-SP:
Dafne C. B. Silva, Rodrigo G. Arduini; Hospital e Mater-
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